Evaluation of P1'-Diversified Phosphinic Peptides Leads to the Development of Highly Selective Inhibitors of MMP-11

Journal of Medicinal Chemistry

Volumn 47, Issue 2, 2004, Pages 325-336

  Matziari, Magdalini ^a   Beau, Fabrice ^b   Cuniasse, Philippe ^b   Dive, Vincent ^b   Yiotakis, Athanasios ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b DIF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; MATRILYSIN; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; PHOSPHINIC ACID DERIVATIVE; STROMELYSIN 3; (1 BENZYLOXYCARBONYLAMINO 2 PHENYLETHYL) (2 (1 CARBAMOYL 2 (1H INDOL 3 YL)ETHYLCARBAMOYL) 3 (2 METHOXYPHENYLSULFANYL)PROPYL)PHOSPHINIC ACID; (1-BENZYLOXYCARBONYLAMINO-2-PHENYLETHYL)-(2-(1-CARBAMOYL-2-(1H-INDOL-3-YL)ETHYLCARBAMOYL)-3-(2-METHOXYPHENYLSULFANYL)PROPYL)PHOSPHINIC ACID; INDOLE DERIVATIVE; METALLOPROTEINASE; PEPTIDE;

ARTICLE; BREAST CANCER; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; GENE OVEREXPRESSION; MOLECULAR MODEL; REACTION ANALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

INDOLES; MATRIX METALLOPROTEINASE 11; METALLOENDOPEPTIDASES; MODELS, MOLECULAR; PEPTIDES; PHOSPHINIC ACIDS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0346333073     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0308491     Document Type: Article

References (33)

1. Zucker, S.; Cao, J.; Chen, W. T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000, 19, 6642-50.
2. Coussens, L.; M.; Fingleton, B.; Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 2002, 295, 2387-92.
3. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2, 161-74.
4. Overall, C. M.; Lopez-Otin, C. Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nat. Rev. Cancer 2002, 2, 657-72.
5. Feldman, A. M.; Li, Y. Y.; McTiernan, C. F. Matrix metalloproteinases in pathophysiology and treatment of heart failure. Lancet 2001, 357, 654-5.
6. Creemers, E. E.; Cleutjens, J. P.; Smits, J. F.; Daemen, M. J. Matrix metalloproteinase inhibition after myocardial infarction: A new approach to prevent heart failure? Circ. Res. 2001, 89, 201-10.
7. Babine, R. E.; Bender, S. L. Molecular Recognition of Protein-Ligand Complexes: Applications to Drug Design. Chem. Rev. 1997, 97, 1359-1472.
8. Lovejoy, B.; Welch, A. R.; Carr, S.; Luong, C.; Broka, C.; Hendricks, R. T.; Campbell, J. A.; Walker, K. A.; Martin, R.; Van Wart, H.; Browner, M. F. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nat. Struct. Biol. 1999, 6, 217-21.
9. Basset, P.; Bellocq, J. P.; Wolf, C.; Stoll, I.; Hutin, P.; Limacher, J. M.; Podhajcer, O. L.; Chenard, M. P.; Rio, M. C.; Chambon, P. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990, 348, 699-704.
10. Murphy, G.; Segain, J. P.; O'Shea, M.; Cockett, M.; Ioannou, C.; Lefebvre, O.; Chambon, P.; Basset, P. The 28-kDa N-terminal domain of mouse stromelysin-3 has the general properties of a weak metalloproteinase. J. Biol. Chem. 1993, 268, 15435-41.
11. Pei, D.; Weiss, S. J., Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 1995, 375, 244-7.
12. Boulay, A.; Masson, R.; Chenard, M. P.; El Fahime, M.; Cassard, L.; Bellocq, J. P.; Sautes-Fridman, C.; Basset, P.; Rio, M. C. High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res. 2001, 61, 2189-93.
13. Vassiliou, S.; Mucha, A.; Cuniasse, P.; Georgiadis, D.; Lucet-Levannier, K.; Beau, F.; Kannan, R.; Murphy, G.; Knauper, V.; Rio, M. C.; Basset, P.; Yiotakis, A.; Dive, V. Phosphinic pseudotripeptides as potent inhibitors of matrix-metalloproteinases: A structure-activity study. J. Med. Chem. 1999, 42, 2610-2620.
14. Cursio, R.; Mari, B.; Louis, K.; Rostagno, P.; Saint-Paul, M. C.; Giudicelli, J.; Bottero, V.; Anglard, P.; Yiotakis, A.; Dive, V.; Gugenheim, J. ; Auberger, P. Rat liver injury after normothermic ischemia is prevented by a phosphinic matrix metalloproteinase inhibitor. FASEB J. 2002, 16, 93-5.
15. Dive, V.; Cotton, J.; Yiotakis, A.; Michaud, A.; Vassiliou, S.; Jiracek, J.; Vazeux, G.; Chauvet, M. T.; Cuniasse, P.; Corvol, P. RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 4330-5.
16. Junot, C.; Gonzales, M. F.; Ezan, E.; Cotton, J.; Vazeux, G.; Michaud, A.; Azizi, M.; Vassiliou, S.; Yiotakis, A.; Corvol, P.; Dive, V. RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis. J. Pharmacol. Exp. Ther. 2001, 297, 606-11.
17. Dive, V.; Lucet-Levannier, K.; Georgiadis, D.; Cotton, J.; Vassiliou, S. ; Cuniasse, P.; Yiotakis, A. Phosphinic peptide inhibitors as tools in the study of the function of zinc metallopeptidases. Biochem. Soc. Trans. 2000, 28, 455-60.
18. Boyd, E. A.; Boyd, M. E.; Loh, V. M. Facile synthesis of functionalised phenylphosphinic acid derivatives. Tetrahedron Lett. 1996, 37, 1651-1654.
19. Thottathil, J. K.; Ryono D. E.; Przybyla. C. A.; Moniot, J. L.; Neubeck, R. Preparation of phosphinic acids: Michael additions of phosphonous acids-esters to conjugated systems. Tetrahedron Lett. 1984, 25, 4741-4744.
20. Baylis, E. K.; Campbell, C. D.; Dingwall, J. D. 1-Aminoalkylphosphonous Acids. Part 1. Isosters of the Protein Amino Acids. J. Chem. Soc., Perkin Trans. 1 1984, 2845-2853.
21. Yiotakis, A.; Vassiliou, S.; Jiracek, J.; Dive, V. Protection of the Hydroxyphosphinyl Function of Phosphinic Dipeptides by Adamantyl. Application to the Solid-Phase Synthesis of Phosphinic Peptides. J. Org. Chem. 1996, 61, 6601-6605.
22. Allen, M.; C.; Fuhrer, W.; Tuck, B.; Wade, R.; Wood, J. M. Renin Inhibitors. Synthesis of Transition-State Analogue Inhibitors Containing Phosphorus Acid Derivatives at the Scissile Bond. J. Med. Chem. 1989, 32, 1652-1661.
23. Matziari, M.; Georgiadis, D.; Dive, V.; Yiotakis, A. Convenient Synthesis and Diversification of Dehydroalaninyl Phosphinic Peptide Analogues. Org. Lett. 2001, 3, 659-662.
24. Gall, A. L.; Ruff, M.; Kannan, R.; Cuniasse, P.; Yiotakis, A.; Dive, V.; Rio, M. C.; Basset, P.; Moras, D. Crystal structure of the stromelysin-3 (MMP-11) catalytic domain complexed with a phosphinic inhibitor mimicking the transition-state. J. Mol. Biol. 2001, 307, 577-86.
25. Mucha, A.; Cuniasse, P.; Kannan, R.; Beau, F.; Yiotakis, A.; Basset, P.; Dive, V. Membrane type-1 matrix metalloprotease and stromelysin-3 cleave more efficiently synthetic substrates containing unusual amino acids in their P1′ positions. J. Biol. Chem. 1998, 273, 2763-8.
26. Shalinsky, D. R.; Brekken, J.; Zou, H.; McDermott, C. D.; Forsyth, P.; Edwards, D.; Margosiak, S.; Bender, S.; Truitt, G.; Wood, A.; Varki, N. M.; Appelt, K. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann. N.Y. Acad. Sci. 1999, 236-70.
27. Moy, F. J.; Chanda, P. K.; Chen, J.; Cosmi, S.; Edris, W.; Levin, J. I.; Rush, T. S.; Wilhelm, J.; Powers, R. Impact of mobility on structure-based drug design for the MMPs. J. Am. Chem. Soc. 2002, 124, 12658-9.
28. Beckett, R. P.; Whittaker, M. Matrix metalloproteinase inhibitors. Exp. Opin. Ther. Patents 1998, 8, 259-2.
29. Bode, W.; Grams, F.; Reinemer, P.; Gomis-Ruth, F. X.; Baumann, U.; McKay, D. B.; Stocker, W. The metzincin-superfamily of zinc-peptidases. Adv. Exp. Med. Biol. 1996, 389, 1-11.
30. Bode, W.; Fernandez-Catalan, C.; Tschesche, H.; Grams, F.; Nagase, H.; Maskos, K. Structural properties of matrix metalloproteinases. Cell. Mol. Life Sci. 1999, 55, 639-52.
31. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations. J. Comput. Chem. 1983, 4, 187-217.
32. MacKerell, A. D.; Bashford D.; Bellott, M.; Dunbrack, R. L.; Evanseck, J. D.; Field, M. J.; Fischer, S.; Gao, J.; Guo, H.; Ha, S.; Joseph-McCarthy, D.; Kucnhir, L.; Kuczera, K.; Lau, F. T. K.; Mattos, C.; Michnick, S.; Ngo, T.; Nguyen, D. T.; Prodhom, B.; Reiher, W. E.; Roux, B.; Schlenkrick, M.; Smith, J. C.; Stote, R.; Straub, J.; Watanabe, M.; Wiorkiewicz-Kuczera, J.; Yin, D.; Karplus, M. All-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins. J. Phys. Chem. B 1998, 102, 3586-3616.
33. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Zakrzewski, V. G.; Montgomery, J. A.; Stratmann, Jr., R. E.; Burant, J. C.; Dapprich, S.; Millam, J. M.; Daniels, A. D.; Kudin, K. N.; Strain, M. C.; Farkas, O.; Tomasi, J.; Barone, V.; Cossi, M.; Cammi, R.; Mennucci, B.; Pomelli, C.; Adamo, C.; Clifford, S.; Ochterski, J.; Petersson, G. A.; Ayala, P. Y.; Cui, Q.; Morokuma, K.; Salvador, P.; Dannenberg, J. J.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Cioslowski, J. ; Ortiz, J. V.; Baboul, A. G.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Andres, J. L.; Gonzalez, C.; Head-Gordon, M.; Replogle, E. S.; Pople, J. A. Gaussian 98 (Revision A.11.3); Gaussian, Inc., Pittsburgh, PA, 2002.